Welcome to our dedicated page for Alto Neuroscienc SEC filings (Ticker: ANRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alto Neuroscience Inc. (ANRO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Alto is a clinical-stage biopharmaceutical company listed on the New York Stock Exchange, and its filings offer structured information on material events, financing transactions, corporate governance, and other matters relevant to shareholders and analysts.
Alto’s recent filings include multiple Form 8-K current reports. These documents describe events such as private placement agreements for common stock and pre-funded warrants, termination of an at-the-market sales agreement, option repricing for employee and consultant stock options, board and committee changes, and the appointment of new directors. Certain 8-K filings also reference press releases that report quarterly financial results, clinical and regulatory updates for programs like ALTO-207 and ALTO-101, and corporate financing developments.
Through these filings, users can review details on Alto’s status as an emerging growth company, its NYSE listing under the symbol ANRO, and its use of equity-based compensation and inducement grants under NYSE rules. The filings also identify Alto’s Mountain View, California location and summarize key agreements, such as securities purchase agreements and registration rights agreements related to private placements.
On Stock Titan, Alto’s SEC filings are updated as new documents are posted to the EDGAR system. AI-powered tools can help summarize lengthy filings and highlight sections related to clinical programs, capital structure changes, and governance items, allowing users to more quickly understand the substance of each report without reading every page in detail.
Alto Neuroscience reported results for the fiscal quarter ended June 30, 2025; a press release is furnished as Exhibit 99.1 to this report.
The company’s Board increased from five to six members and appointed Ramiro (Raymond) Sanchez, M.D., age 64, as an independent Class II director with a term expiring at the 2026 Annual Meeting. Dr. Sanchez brings more than 20 years of life sciences experience, including roles as Chief Medical Officer and senior global clinical development positions, and currently serves as a Senior Advisor at Bain Capital Life Sciences.
Under the Non-Employee Director Compensation Policy Dr. Sanchez will receive an initial option grant to purchase 30,574 shares vesting in equal monthly installments over three years, an annual option grant of 15,287 shares, a $40,000 annual cash retainer plus a $5,000 annual NCGC retainer, and standard indemnification. The Board also rebalanced director classes and updated committee memberships.
Alto Neuroscience (NYSE:ANRO) filed an 8-K announcing a material clinical milestone. A press release (Ex. 99.1) reports positive pharmacodynamic results and biomarker identification from an exploratory Phase 2 proof-of-concept trial of lead candidate ALTO-203.
Key points:
- Phase 2 study delivered a favorable pharmacodynamic signal; no numerical efficacy or safety data were released.
- New biomarker is positioned as a tool for future patient selection and trial design.
- No changes to strategy, guidance, or capital structure disclosed.
The update may de-risk ALTO-203 ahead of planned later-stage studies and could influence investor sentiment.